TriSalus reports $12.9m TriNav sales, $46m–$48m outlook and new 2027 Medicare rates

TriSalus Life Sciences said sales of its TriNav infusion system reached $12.9 million in the third quarter of 2026, an 11% increase. The company disclosed the figure on 10 November alongside a revised full-year 2026 revenue range of $46 million to $48 million.

The information available does not say whether the new range is higher or lower than the previous one, nor what the company assumes for the final quarter. It also gives no comparison period for the 11% figure. Readers should check the full earnings release before drawing conclusions about momentum.

On the regulatory front, the US Food and Drug Administration has cleared TriNav Advance, a device intended to deliver therapy under pressure into small, distal blood vessels. No details were available on the clearance pathway, the date of clearance or the launch timing.

The company also drew attention to final 2027 payment decisions from the Centers for Medicare & Medicaid Services. Under the hospital outpatient system, the rate for HCPCS code C8004 rises to roughly $20,910. For procedures done in office-based labs, CMS set a national payment of about $13,800 under a new code, G0577. The material does not state the 2026 rates, so the size of the change for C8004 cannot be calculated from the facts available.